AstraZeneca has received FDA approval for IMJUDO (tamelimumab) to treat certain patients with primary sclerosing cholangitis (PSC), marking the company's first-ever获批治疗该罕见自身免疫肝脏疾病。 This approval for the intravenous immunosuppressant positions AstraZeneca as a key entrant in the expanding BTK-inhibitor landscape and creates a potential name-share opportunity with the company's widely prescribed ulcerative colitis therapy, IMDEVIMAB.